Matheson


News and Insights

Print this page

Search News & Insights


Matheson advises Allergan on $66 billion merger with Actavis

AUTHOR(S): Patrick Spicer, John Ryan, George Brady, Shane Hogan
PRACTICE AREA GROUP: Corporate
DATE: 19.11.2014

Matheson has advised Allergan on a definitive merger agreement under which Actavis will acquire Allergan in a $66 billion cash and stock transaction. The merger will create one of the top 10 global pharmaceutical companies by revenue, with combined annual pro forma revenues of over $23 billion expected in 2015. 

The Matheson team advising Allergan included corporate partners Patrick Spicer and George Brady, tax partner Shane Hogan and Head of US Offices, John Ryan. This continues Matheson’s track record of advising on high profile international M&A transactions. Matheson recently advised Auxilium Pharmaceuticals Inc. on its $2.6 billion merger with Endo International plc. Matheson also advised Questcor Pharmaceuticals on its $5.6 billion merger with Mallinckrodt and is advising Perella Weinberg Partners as financial adviser to Medtronic on its $42.9 billion acquisition of Covidien. Matheson advised Actavis on its $8.5 billion acquisition of Dublin-based Warner Chilcott as well as advising Royalty Pharma on its $6.5 billion hostile bid for Elan Corporation, the Irish biotechnology company in 2013. 

The transaction has been unanimously approved by the Boards of Directors of both companies. Subject to shareholder and regulatory approval, the transaction is expected to close in the second quarter of 2015.

BACK TO LISTING

Matheson Snapshot


About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)